Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs

HIV Medicine

Volumn 8, Issue 3, 2007, Pages 156-163

  Le Moing, V ^a,i   Thiebaut R ^b   Chene G ^c   Sobel, A ^d,u   Massip, P ^e,an   Collin, F ^c   Meyohas, M C ^f   Al Kaied F ^g   Leport, C ^g   Raffi, F ^h,ad   Salamaon, R ^ap   Moatti, J P ^ap   Pierret, J ^ap   Spire, B ^ap   Brun Vezinet F ^ap   Fleury, H ^ap   Masquelier, B ^ap   Peytavin, G ^ap   Garraffo, R ^ap   Costagliola, D ^ap   Dellamonica, P ^ae,ap   Katlama, C ^ap   Meyer, L ^ap   Morin, M ^ap   Salmon, D ^ag   Schmit, J L ^j   Chennebault, J M ^k   Faller, J P ^l   Dupond, J L ^m   Estavoyer, J M ^m   Laurent, R ^m   Guillevin, L ⁿ   Beylot, J ^o   Dupon, M ^o   Longy Bousier, M ^o   Ragnaud, J M ^o   Granier, P ^p   Garre M ^q   Verdon, R ^r   Veyssier, P ^s   Devidas, A ^t   Portier, H ^v   Perronne, C ^w   Lagarde, P ^x   Ceccaldi, J ^y   Peyramond, D ^z   Allard, C ^aa   Reynes, J ^ab   May, T ^ac   Cassuto, J P ^ae   Arsac, P ^af   Bricaire, F ^ag   Cabane, T ^ag   Caulin, C ^ag   Cessot, T ^ag   Girard, P M ^ag   Herson, S ^ag   Molina, T M ^ag   Pialoux, G ^ag   Vilde T L ^ag   Yeni D ^ag   Becq Giraudon, B ^ah   Remy G ^ai   Michelet, C ^aj   Lucht, F ^o   Debord, T ^ak   Lang, J M ^al   de Jaureguiberry, J P ^am   Choutet, P ^ao   more..

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g BICHAT HOSPITAL   (France)

^h HÔTEL DIEU   (France)

ⁱ GUI DE CHAULIAC HOSPITAL   (France)

^j Clinical Center   (France)

^k Clinical Center   (France)

^l Clinical Center   (France)

^m Clinical Center   (France)

ⁿ Clinical Center   (France)

^o Clinical Center   (France)

^p Clinical Center   (France)

^q Clinical Center   (France)

^r Clinical Center   (France)

^s Clinical Center   (France)

^t Clinical Center   (France)

^u Clinical Center   (France)

^v Clinical Center   (France)

^w Clinical Center   (France)

^x Clinical Center   (France)

^y Clinical Center   (France)

^z Clinical Center   (France)

^aa Clinical Center   (France)

^ab Clinical Research Center   (France)

^ac Clinical Center   (France)

^ad Clinical Center   (France)

^ae Clinical Center   (France)

^af Clinical Center   (France)

^ag Clinical Center   (France)

^ah Clinical Center   (France)

^ai Clinical Center   (France)

^aj Clinical Center   (France)

^ak Clinical Center   (France)

^al Clinical Center   (France)

^am Clinical Center   (France)

^an Clinical Center   (France)

^ao Clinical Center   (France)

^ap NONE

more..

Author keywords

Increase in CD4 count; Long term; Persistent virological response; Prospective cohort study

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 34250335089     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00446.x     Document Type: Article

References (21)

1. Le Moing V, Thiébaut R, Chêne G et al. Predictors of long-term increase of CD4+ cell counts in human immunodeficiency virus-infected patients initiating a protease inhibitor-containing regimen. J Infect Dis 2002; 185: 471-480.
2. Kousignian I, Abgrall S, Duval X et al. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34: 50-57.
3. Smith CJ, Sabin CA, Youle MS et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190: 1860-1868.
4. Tarwater PM, Margolick JB, Jin J et al. Increase and plateau of CD4 T-cell counts in the 31/2 years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 168-175.
5. Valdez H, Connick E, Smith KY et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16: 1859-1866.
6. Kauffmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16: 359-367.
7. Viard JP, Burgard M, Huber JB et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18: 45-49.
8. Smith CJ, Sabin CA, Lampe FC et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003; 17: 963-969.
9. Hunt PW, Deeks SG, Rodriguez B et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-1915.
10. Smith K, Aga E, Bosch RJ et al. Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS 2004; 18: 1953-1956.
11. Grabar S, Kousignian I, Sobel A et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18: 2029-2038.
12. Giordano TP, Wright JA, Hasan MQ et al. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003; 37: 433-437.
13. Barreiro P, Soriano V, Casas E, Gonzalez-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002; 16: 245-249.
14. Dronda F, Moreno S, Moreno A, Casado JL, Perez-Elias MJ, Antela A. Long-term outcomes among antiretroviral naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. Clin Infect Dis 2002; 35: 1005-1009.
15. Le Moing V, Chêne G, Carrieri MP et al. Predictors of virological rebound in a cohort of HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16: 21-29.
16. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV cohort study. Lancet 2000; 356: 1800-1805.
17. Farmer Miller M, Haley C, James Koziel M, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: A meta-analysis. Clin Infect Dis 2005; 41: 713-720.
18. Notemans DW, Pakker NG, Hamann D et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected patients. J Infect Dis 1999; 180: 1050-1056.
19. Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2005; 191: 348-357.
20. Lederman HM, Williams PL, Wu JW et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis 2003; 88: 794-803.
21. Lewden C APROCO and Aquitaine Study Groups. Responders to antiretroviral treatment over 500 CD4/mm 3 reach the same mortality rates as general population: APROCO and Aquitaine cohorts, France. 10th European AIDS Conference. Dublin, Ireland, Nor 2005 [Poster PE18.4/8].